Conference abstract
Improvement in antihepatitis C virus resistance with ribavirin and pegylated- interferon-alpha 2b using an
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Chronic hepatitis C (CHC) is a serious global medical problem necessitating more eff ective treatment. Cyclic and periodic IFN-treatment (CPIT) consisting of induction-treatment with natural IFN-beta followed by maintenance-treat ment with natural IFN-alpha could prevent viral-breakthrough and achieve rapid-virologic-response (RVR) and early-VR (EVR) in CHC. Th e effi cacy and immune-response of RBV+PEGIFN-alpha 2b using induction-approach with CPIT (novel combination treatment: NCT) in 7 CHC patients with genotype-1b, high viral load and ISDR with wild and intermediate type were evaluated. A biometric multiplex serum cytokine assay was utilized to characterize the immunomodulatory eff ect. RVR and EVR were 7/7 and 7/7. Viral titers dropped below detectable levels in 5 patients with sustained-VR (SVR) before the end of CPIT (early-virologic-responder: EAVR), and 2 patients without SVR aft er the end of CPIT (late-virologic-responder: LA VR). At baseline, in EAVR compared with the controls, IL-6 and IL-15, CXCL-8 and CXCL-10 levels were signifi cantly higher (p<0.05); IL- 10 and IL-13 levels were signifi cantly lower (p<0.05); and the IL-12 level was lower. In LAVR; GM-CSF, CXCL-8 and CXCL-10 and CCL-4 levels were signifi cantly higher (p<0.05); and IL-10 and IL-12 were lower than the controls. In EAVR but not LAVR, the IL-12 and IL-15 increased, and the CCXL-8 and CCL-4 decreased signifi cantly (p<0.05). In conclusion, NCT induced viral clearance leading to improvement in the innate-immune-response resulting in SVR in CHC with genotype-1b and high viral load. It is feasible to treat diffi cult-to-treat-CHC with NCT. An additional study is in progress to evaluate viral effi cacy in a controlled manner.
Keywords
Subjects
Vaccines & ImmunisationAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Vaccines & Vaccination
- SubjectVaccines & Immunisation
- BylineArticles whose byline prints “Yutaka Kishida”